BHVNBiohaven Ltd.

NYSE biohavenpharma.com


$ 33.57 $ 0.12 (0.36 %)    

Friday, 21-Jun-2024 15:59:50 EDT
QQQ $ 478.56 $ -0.61 (-0.13 %)
DIA $ 391.56 $ -0.73 (-0.19 %)
SPY $ 544.47 $ -0.73 (-0.13 %)
TLT $ 93.75 $ 0.00 (0 %)
GLD $ 214.79 $ -3.38 (-1.55 %)
$ 33.56
$ 33.33
$ 0.00 x 0
$ 33.59 x 200
$ 33.00 - $ 34.35
$ 16.45 - $ 62.21
3,044,137
na
2.29B
$ 1.80
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 07-31-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-23-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rbc-capital-reiterates-outperform-on-biohaven-maintains-59-price-target

RBC Capital analyst Leonid Timashev reiterates Biohaven (NYSE:BHVN) with a Outperform and maintains $59 price target.

 hc-wainwright--co-reiterates-buy-on-biohaven-maintains-59-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Buy and maintains $59 price target.

 cantor-fitzgerald-reiterates-overweight-on-biohaven

Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.

 biohaven-stock-stumbles-as-protein-degrading-drug-falls-short-of-expectations-in-early-stage-study

Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.

 whats-going-on-with-biohaven-stock-wednesday

The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two di...

 biohaven-highlights-development-and-regulatory-advances-across-therapeutic-areas-and-progress-of-degrader-pipeline-at-2024-investor-rd-day

Reports new interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecula...

 this-biotech-stock-is-poised-for-80-upside-with-breakthrough-in-obesity-drug-market-says-jpmorgan

The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the s...

 hc-wainwright--co-maintains-buy-on-biohaven-lowers-price-target-to-59

HC Wainwright & Co. analyst Douglas Tsao maintains Biohaven (NYSE:BHVN) with a Buy and lowers the price target from $63 ...

 ubs-maintains-buy-on-biohaven-raises-price-target-to-60

UBS analyst Ashwani Verma maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $59 to $60.

 cantor-fitzgerald-reiterates-overweight-on-biohaven

Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.

 biohaven-reports-pricing-of-public-offering-of-5609m-of-its-common-shares-at-41-per-share

The gross proceeds from the offering are expected to be approximately $230 million before deducting underwriting discounts and ...

 biohaven-announces-200m-public-offering-of-common-shares

Biohaven Ltd. (NYSE:BHVN), a biopharmaceutical company focused on the discovery, development and commercialization of life-chan...